Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Express Scripts
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for VT-1161

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for VT-1161?

VT-1161 is an investigational drug.

There have been 7 clinical trials for VT-1161. The most recent clinical trial was a Phase 2 trial, which was initiated on August 23rd 2018.

The most common disease conditions in clinical trials are Candidiasis, Vulvovaginal, Candidiasis, and Tinea. The leading clinical trial sponsors are Viamet, Mycovia Pharmaceuticals Inc., and [disabled in preview].

There are four US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for VT-1161
TitleSponsorPhase
A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal CandidiasisMycovia Pharmaceuticals Inc.Phase 3
A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)Mycovia Pharmaceuticals Inc.Phase 3
A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)Mycovia Pharmaceuticals Inc.Phase 3

See all VT-1161 clinical trials

Clinical Trial Summary for VT-1161

Top disease conditions for VT-1161
Top clinical trial sponsors for VT-1161

See all VT-1161 clinical trials

US Patents for VT-1161

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VT-1161   Start Trial Antifungal compound process Mycovia Pharmaceuticals, Inc. (Durham, NC) U.S. Department of Health and Human Services (Washington, DC)   Start Trial
VT-1161   Start Trial Antifungal compound process Mycovia Pharmaceuticals, Inc. (Durham, NC) The United States of America, as represented by the Department of Health and Human Services (Washington, DC)   Start Trial
VT-1161   Start Trial Antifungal compound process MYCOVIA PHARMACEUTICALS, INC. (Durham, NC)   Start Trial
VT-1161   Start Trial Antifungal compounds and processes for making Viamet Pharmaceuticals, Inc. (Durham, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VT-1161

Drugname Country Document Number Estimated Expiration Related US Patent
VT-1161 Australia 2015231234 2034-03-19   Start Trial
VT-1161 Canada 2942972 2034-03-19   Start Trial
VT-1161 European Patent Office 3119755 2034-03-19   Start Trial
VT-1161 Japan 2017509646 2034-03-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
AstraZeneca
Johnson and Johnson
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.